The Reeve Woods Eye Center is pleased to share experience and glaucoma experience and availability of the Hydrus Glaucoma implant for cataract surgery. Benefits of the implant are reduced intraocular pressure and glaucoma control. 5-year data from the FDA Trial demonstrate significant benefit for glaucoma control for patients including over a 60% reduction of need for glaucoma surgery (filtration or cilioablative glaucoma surgery), and over 70% reduction of needing at least 1 medication for mild to moderate glaucoma.

The Hydrus stent functions to lower eye pressure by opening up the eye’s natural drainage system. The Hydrus stent is placed inside Schlemm’s canal of the angle of the eye to stent open the canal and lower eye pressure, opening up the Trabecular Meshwork. Besides this stretching effect on the meshwork, the Hydrus also has an open end of the stent inside the anterior chamber, allowing flow into the tubular lumen of the stent, and lowering pressure as fluid leaves the eye.

Patients should discuss with their doctor the risks and benefits of surgery, their specific surgery goals, and their candidacy for the Hydrus implant.

​​​​​​​Our surgeons perform Hydrus stents as well as other glaucoma technologies that are indicated for the benefit of glaucoma patients needing intraocular pressure control.